英語ページ

Publications 2015

  1. Amin Al Olama, A., Benlloch, S., Antoniou, A. C., Giles, G. G., Severi, G., Neal, D. E., Hamdy, F. C., Donovan, J. L., Muir, K., Schleutker, J., Henderson, B. E., Haiman, C. A., Schumacher, F. R., Pashayan, N., Pharoah, P. D., Ostrander, E. A., Stanford, J. L., Batra, J., Clements, J. A., Chambers, S. K., Weischer, M., Nordestgaard, B. G., Ingles, S. A., Sorensen, K. D., Orntoft, T. F., Park, J. Y., Cybulski, C., Maier, C., Doerk, T., Dickinson, J. L., Cannon-Albright, L., Brenner, H., Rebbeck, T. R., Zeigler-Johnson, C., Habuchi, T., Thibodeau, S. N., Cooney, K. A., Chappuis, P. O., Hutter, P., Kaneva, R. P., Foulkes, W. D., Zeegers, M. P., Lu, Y. J., Zhang, H. W., Stephenson, R., Cox, A., Southey, M. C., Spurdle, A. B., FitzGerald, L., Leongamornlert, D., Saunders, E., Tymrakiewicz, M., Guy, M., Dadaev, T., Little, S. J., Govindasami, K., Sawyer, E., Wilkinson, R., Herkommer, K., Hopper, J. L., Lophatonanon, A., Rinckleb, A. E., Kote-Jarai, Z., Eeles, R. A. and Easton, D. F. (2015)Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev. 24(7): 1121-9.
  2. Inoue, T., Tsuchiya, N., Narita, S., Tsuruta, H., Akihama, S., Saito, M., Satoh, S., Habuchi, T. (2015) Successful introduction of laparoendoscopic single-site donor nephrectomy after experience with laparoscopic single-site plus-one trocar donor nephrectomy. J Endourol. 29(4): 435-442.
  3. Kanda, S., Tsuchiya, N., Narita, S., Inoue, T., Huang, M., Chiba, S., Akihama, S., Saito, M., Numakura, K., Tsuruta, H., Satoh, S., Saito, S., Ohyama, C., Arai, Y., Ogawa, O., Habuchi, T. (2015) Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival. Int J Cancer. 136(1): 74-82.
  4. Kashima, S., Tsuchida, S., and Koizumi H. (2015) Tocilizumab and adalimumab in an 18q deletion syndrome patient with chronic arthritis. Clin Exp Rheumatol. 2015; 33(1): 130-131.
  5. Kofuji, S., Kimura, H., Nakanishi, H., Nanjo, H., Takasuga, S., Liu, H., Eguchi, S., Nakamura, R., Itoh, R., Ueno, N., Asanuma, K., Huang, M., Koizumi, A., Habuchi, T., Yamazaki, M., Suzuki, A., Sasaki, J., Sasaki, T. (2015) INPP4B Is a Ptdlns(3,4,5)P3 Phospahtase That Can Act as a Tumor Suppressor. Cancer Discov. 5(7): 730-739.
  6. Koie, T., Mitsuzuka, K., Narita, S., Yoneyama, T., Kawamura, S., Kaiho, Y., Tsuchiya, N., Tochigi, T., Habuchi, T., Arai, Y., Ohyama, C. (2015) A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens. Scand J Urol. 49(2): 103-107.
  7. Koie, T., Mitsuzuka, K., Narita, S., Yoneyama, T., Kawamura, S., Tsuchiya, N., Tochigi, T., Habuchi, T., Arai, Y., Ohyama, C. (2015) Efficiency of pretreatment risk stratification systems for prostate cancer in a Japanese population treated with radical prostatectomy. Int J Urol. 22(1): 70-73.
  8. Koie, T., Mitsuzuka, K., Yoneyama, T., Narita, S., Kawamura, S., Kaiho, Y., Tsuchiya, N., Tochigi, T., Habuchi, T., Arai, Y., Ohyama, C., Tobisawa, Y. (2015) Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis. Int J Clin Oncol. 20(5): 1018-25.
  9. Koie, T., Mitsuzuka, K., Yoneyama, T., Narita, S., Kawamura, S., Kaiho, Y., Tsuchiya, N., Tochigi, T., Habuchi, T., Arai, Y., Ohyama, C., Tobisawa, Y. (2015) Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy. Int J Clin Oncol. 20(1): 176-181.
  10. Kojima, T., Kawai, K., Tsuchiya, K., Abe, T., Shinohara, N., Tanaka, T., Masumori, N., Yamada, S., Arai, Y., Narita, S., Tsuchiya, N., Habuchi, T., Nishiyama, H. (2015) Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor. Int J Urol. 22(10): 923-927.
  11. Mitsuzuka, K., Narita, S., Koie, T., Kaiho, Y., Tsuchiya, N., Yoneyama, T., Kakoi, N., Kawamura, S., Tochigi, T., Ohyama, C., Habuchi, T., Arai, Y. (2015) Lymphovascular invasion is significantly associated with biochemical relapse after radical prostatectomy even in patients with pT2N0 negative resection margin. Prostate Cancer Prostatic Dis. 18: 25-30.
  12. Narita, S., Mitsuzuka, K., Tsuchiya, N., Koie, T., Kawamura, S., Ohyama, C., Tochigi, T., Yamaguchi, T., Arai, Y., Habuchi, T.; Michinoku Japan Urological Cancer Study Group. (2015) Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy. Int J Urol. 22(11): 1029-35.
  13. Niioka, T., Kagaya, H., Saito, M., Inoue, T., Numakura, K., Habuchi, T., Satoh, S. Miura, M. (2015) Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation. Int J Mol Sci. 16(1): 1840-54.
  14. Numakura, K. (2015) Editorial Comment from Dr Numakura to Clinicopathological characteristics of Xp11.2 translocation renal cell carcinoma in adolescents and adults: Diagnosis using immunostaining of transcription factor E3 and fluorescence in situ hybridization analysis. Int J Urol. 23(2): 147.
  15. Numakura, K., Kagaya, H., Yamamoto, R., Komine, N., Saito, M., Tsuruta, H., Akihama, S., Inoue, T., Narita, S., Tsuchiya, N., Habuchi, T., Niioka, T., Miura, M., Satoh, S. (2015) Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation. Dis Markers. 2015, 179434.
  16. Numakura, K., Tsuchiya, N., Takahashi, M., Tsuruta, H., Akihama, S., Saito, M., Inoue, T., Narita, S., Huang, M., Satoh, S., Habuchi, T. (2015) Clinical benefits of tubeless umbilical cutaneous ureterostomy. Can Urol Assoc J. 9(5-6): E379-383.
  17. Shire, A., Lomberk, G., Lai, J. P., Zou, H., Tsuchiya, N., Aderca, I., Moser, C. D., Gulaid, K. H., Oseini, A., Hu, C., Warsame, O., Jenkins, R. B., Roberts, L. R. (2015) Restoration of Epigenetically Silenced Sulfatase 1 Expression by 5-Aza-2'-Deoxycytidine Sensitizes Hepatocellular Carcinoma Cells to Chemotherapy-Induced Apoptosis. Med Epigenet. 3(1): 1-18.

メニューを開く